Emergent BioSolutions (EBS) Enterprise Value (2010 - 2026)

Emergent BioSolutions' Enterprise Value history runs 17 years deep, the most recent figure standing at -$161.5 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 5.69% year-over-year to -$161.5 million; the TTM figure through Mar 2026 stood at -$161.5 million (down 5.69% YoY), while the FY2025 annual figure was -$209.1 million, down 98.01% from the prior year.
• Enterprise Value was -$161.5 million for Q1 2026 at Emergent BioSolutions, up from -$209.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$71.0 million in Q2 2024 to a low of -$642.6 million in Q4 2022.
• Historically, Enterprise Value has averaged -$226.6 million across 5 years, with a median of -$161.5 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value surged 82.62% in 2023, then slumped 281.69% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$642.6 million in 2022, then soared by 82.62% to -$111.7 million in 2023, then increased by 5.46% to -$105.6 million in 2024, then plunged by 98.01% to -$209.1 million in 2025, then increased by 22.76% to -$161.5 million in 2026.
• The last three Enterprise Value figures came in at -$161.5 million (Q1 2026), -$209.1 million (Q4 2025), and -$249.2 million (Q3 2025), per Business Quant data.